A randomized study to assess efficacy and safety of Anaceptrapib when added to ongoing lipid-lowering therapy.

Registry ID

EUCTR2011-004525-27

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Start date

2012-01-03

Completion date

2018-11-13

Last update

2026-08-16

Conditions

• Heterozygous Familial Hypercholesterolemia

Summary

1. Evaluate the efficacy of adding anacetrapib 100 mg for 52 weeks relative to placebo on plasma concentrations of LDL-C (beta quantification method). 2. Evaluate the safety and tolerability of 52 weeks of treatment with anacetrapib 100 mg.

Locations

• , , Czechia
• , , UK
• , , Germany
• , , Netherlands
• , , Spain

Related clinical trials

• A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
• Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, with Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)
• Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
• A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
• Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia

View on source registry